From Financial Modeling Prep: 2025-02-17 01:00:03

In summary, Axsome Therapeutics (NASDAQ: AXSM) is expected to report a decline in earnings despite higher revenues in the upcoming quarter. The company’s negative P/E ratio of -20.30 and high price-to-sales ratio of 18.78 reflect investor caution and high growth expectations. Financial risks are highlighted by a negative enterprise value to operating cash flow ratio of -46.92 and a debt-to-equity ratio of 2.07, but a healthy current ratio of 2.44 suggests short-term stability.



Read more at Financial Modeling Prep:: Axsome Therapeutics’ Quarterly Earnings Preview